Endonovo Therapeutics (OTCMKTS:ENDVD) and Can-Fite BioPharma (NYSE:CANF) Financial Survey

Can-Fite BioPharma (NYSE:CANF) and Endonovo Therapeutics (OTCMKTS:ENDVD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Institutional & Insider Ownership

21.0% of Can-Fite BioPharma shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Can-Fite BioPharma and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%

Analyst Ratings

This is a summary of current ratings and price targets for Can-Fite BioPharma and Endonovo Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0	0	2	0	3.00
Endonovo Therapeutics	0	0	0	0	0.00

Can-Fite BioPharma currently has a consensus target price of $14.50, indicating a potential upside of 2,257.72%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, research analysts plainly believe Can-Fite BioPharma is more favorable than Endonovo Therapeutics.

Risk and Volatility

Can-Fite BioPharma has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

Earnings & Valuation

This table compares Can-Fite BioPharma and Endonovo Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$560,000.00	3.89	-$7.63 million	($1.79)	-0.34
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	N/A	N/A

Endonovo Therapeutics has lower revenue, but higher earnings than Can-Fite BioPharma.

Summary

Can-Fite BioPharma beats Endonovo Therapeutics on 8 of the 11 factors compared between the two stocks.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.